The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence.

Hicks DG, Janarthanan BR, Vardarajan R, Kulkarni SA, Khoury T, Dim D, Budd GT, Yoder BJ, Tubbs R, Schreeder MT, Estopinal NC, Beck RA, Wang Y, Ring BZ, Seitz RS, Ross DT

Open source

DOI
10.1186/1471-2407-10-108
Published
2010 Mar 22
Container
BMC cancer
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/1471-2407-10-108,
  title = {The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence.},
  author = {Hicks DG and Janarthanan BR and Vardarajan R and Kulkarni SA and Khoury T and Dim D and Budd GT and Yoder BJ and Tubbs R and Schreeder MT and Estopinal NC and Beck RA and Wang Y and Ring BZ and Seitz RS and Ross DT},
  year = {2010},
  journal = {BMC cancer},
  doi = {10.1186/1471-2407-10-108},
  url = {https://doi.org/10.1186/1471-2407-10-108}
}

RIS

TY  - JOUR
TI  - The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence.
AU  - Hicks DG
AU  - Janarthanan BR
AU  - Vardarajan R
AU  - Kulkarni SA
AU  - Khoury T
AU  - Dim D
AU  - Budd GT
AU  - Yoder BJ
AU  - Tubbs R
AU  - Schreeder MT
AU  - Estopinal NC
AU  - Beck RA
AU  - Wang Y
AU  - Ring BZ
AU  - Seitz RS
AU  - Ross DT
PY  - 2010
JO  - BMC cancer
DO  - 10.1186/1471-2407-10-108
UR  - https://doi.org/10.1186/1471-2407-10-108
ER  - 

APA

DG, H., BR, J., R, V., SA, K., T, K., D, D., GT, B., BJ, Y., R, T., MT, S., NC, E., RA, B., Y, W., BZ, R., RS, S., & DT, R. (2010). The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence.. BMC cancer. https://doi.org/10.1186/1471-2407-10-108

Source records